Update of safety information for medicinal products containing angiotensin II receptor blockers (ARBs): azilsartan, candesartan, eprosartan, irbesartan, losartan, olmesartan, telmisartan, valsartan [single-component and combination medicinal products], adopted by the PRAC committee during its review of signals discussed at the meeting of 28-31 October 2024
26.12.2024
1370
In accordance with paragraph 8 of Section IV of the Procedure for conducting expert evaluation, the applicant must amend the instruction for medical use of the medicinal product…
Read more